Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2

SIMPLE SUMMARY: Drug resistance is the main cause of sorafenib treatment failure in clinical acute myeloid leukemia (AML) patients, but the mechanism is currently not fully clear. In this study, we analyzed the genetic characteristics of sorafenib-resistant AML cell subclusters using single-cell and...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xi, Ma, Weiwei, Qiu, Guo, Xuan, Li, He, Chong, Zhang, Tian, Wang, Jian, Liu, Qifa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603903/
https://www.ncbi.nlm.nih.gov/pubmed/37887047
http://dx.doi.org/10.3390/biology12101337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603903/
https://www.ncbi.nlm.nih.gov/pubmed/37887047
http://dx.doi.org/10.3390/biology12101337

Ejemplares similares